Care Setting Affects Management of Carotid Artery Stenosis

Share this content:
Care Setting Affects Management of Carotid Artery Stenosis
Care Setting Affects Management of Carotid Artery Stenosis

THURSDAY, March 2, 2017 (HealthDay News) -- For individuals with a diagnosis of carotid artery stenosis, the likelihood of undergoing procedural management is increased for those treated in a fee-for-service system compared with a salary-based setting, according to a study published online March 1 in JAMA Surgery.

Louis L. Nguyen, M.D., M.B.A., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues queried the Department of Defense Military Health System Data Repository for individuals diagnosed with carotid artery stenosis to examine the correlation of the treatment system (fee-for-service physicians in the private sector versus salary-based military physicians) with the odds of procedural intervention versus medical management. Data were included for 10,579 individuals, of whom 12.4 percent underwent at least one procedure.

The researchers found that the odds of undergoing procedural management were significantly higher for patients in the fee-for-service system versus the salary-based system, after adjustment for demographic and clinical factors (odds ratio, 1.629). When patients were stratified by symptom status at presentation, the findings persisted (symptomatic: odds ratio, 2.074; asymptomatic: odds ratio, 1.534).

"Individuals treated in a fee-for-service system were significantly more likely to undergo procedural management for carotid stenosis compared with those in the salary-based setting," the authors write. "These findings remained consistent for individuals with and without symptomatic disease."

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »